Tysabri every eight weeks may cut PML risk

[MSUK]

Preliminary findings from an ongoing study of multiple sclerosis patients suggest the dosing interval for Tysabri can be as much as doubled from the label-recommended standard without sacrificing efficacy, and with potentially less risk of progressive multifocal leukoencephalopathy (PML) -- even among patients with more than average PML risk, researchers claim... Read More - http://www.ms-uk.org/MSnews